Saturday 17 October 2026
Export CMND’s income statement to Excel — free account
Clearmind Medicine Inc.
CMND Healthcare Biotechnology
In the quarter to July 2026, EPS grew 99.4%, free cash flow fell 77.9% and total debt rose 10,410.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.26
0.16
−2.49%
Follow CMND
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 156,847.14 | 17,999.86 | 8,067.20 | 2,947.20 | 139.44 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 262,797.91 | 585,600.00 | 489,600.00 | 11,456.00 | 5,600.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | 0 | 0 | 0 | (7) | (7) | (9) | (5) | (4) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | 0 | 0 | 0 | 0 | (7) | (9) | (5) | (4) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (13.78) | (6.46) | (9.67) | (97.05) | (67,507.50) | (17,032.00) | (676.00) | (303.50) | |||||
| Cash flow | — | — | (7.46) | (3.88) | (10.99) | (73.99) | (37,245.00) | (12,603.00) | (622.91) | (372.80) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (56.00) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (7.46) | (3.88) | (10.99) | (73.99) | (37,301.00) | (12,603.00) | (622.91) | (372.80) | |||||
| Book value | — | — | 16.90 | 8.24 | 20.74 | (37.95) | (11,060.00) | 1,967.00 | 398.41 | 93.91 | |||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | 0 | 0 | (2) | (4) | (6) | (5) | (5) | ||||
| Capex | — | — | 0 | 0 | 0 | 0 | 0 | — | — | — | |||||
| Free cash flow | — | — | 0 | 0 | 0 | (2) | (4) | (6) | (5) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 0 | 0 | (2) | (1) | 1 | 3 | 1 | ||||
| Total debt | — | — | — | — | — | — | 0 | — | 0 | 2 | |||||
| Net debt | — | — | 0 | 0 | 0 | 0 | 0 | (6) | (7) | (4) | |||||
| Shareholders’ equity | — | — | 0 | 0 | 0 | (1) | (1) | 1 | 3 | 1 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (49.32) | (67.35) | (1,158.81) | (809.93) | (254.31) | (79.56) | (57.83) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 0.00 | (56.20) | (73.55) | 140.81 | 116.23 | 14,074.78 | (256.88) | (179.39) | |||||
Negative figures in brackets.
Charts ten years each
Clearmind Medicine Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IOBTQ IO Biotech, Inc. | $3.5M | — (loss-making) | — | — | n/m | +11.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | −23.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $3.2M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $3.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| Median of peers | $3.3M | — | — | −68.22% | — | −12.92% | 13.66% | 0.00% |
Clearmind Medicine Inc. (CMND) key facts
- Clearmind Medicine Inc. (CMND) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CMND traded at $6.26, a market capitalization of $3.3 million.
- Return on equity was −179.4% and debt-to-equity 0.13.